286 related articles for article (PubMed ID: 35493448)
1. Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
Feola S; Russo S; Martins B; Lopes A; Vandermeulen G; Fluhler V; De Giorgi C; Fusciello M; Pesonen S; Ylösmäki E; Antignani G; Chiaro J; Hamdan F; Feodoroff M; Grönholm M; Cerullo V
Front Immunol; 2022; 13():826164. PubMed ID: 35493448
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenoviruses and immunopeptidomics: a convenient marriage.
Garcia-Moure M; Gillard AG; Alonso MM; Fueyo J; Gomez-Manzano C
Mol Oncol; 2024 Apr; 18(4):781-784. PubMed ID: 38561242
[TBL] [Abstract][Full Text] [Related]
3. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.
Feola S; Chiaro J; Martins B; Russo S; Fusciello M; Ylösmäki E; Bonini C; Ruggiero E; Hamdan F; Feodoroff M; Antignani G; Viitala T; Pesonen S; Grönholm M; Branca RMM; Lehtiö J; Cerullo V
Elife; 2022 Mar; 11():. PubMed ID: 35314027
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.
Roy DG; Geoffroy K; Marguerie M; Khan ST; Martin NT; Kmiecik J; Bobbala D; Aitken AS; de Souza CT; Stephenson KB; Lichty BD; Auer RC; Stojdl DF; Bell JC; Bourgeois-Daigneault MC
Nat Commun; 2021 May; 12(1):2626. PubMed ID: 33976179
[TBL] [Abstract][Full Text] [Related]
6. Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.
Ylösmäki E; Malorzo C; Capasso C; Honkasalo O; Fusciello M; Martins B; Ylösmäki L; Louna A; Feola S; Paavilainen H; Peltonen K; Hukkanen V; Viitala T; Cerullo V
Mol Ther; 2018 Sep; 26(9):2315-2325. PubMed ID: 30005865
[TBL] [Abstract][Full Text] [Related]
7. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
[TBL] [Abstract][Full Text] [Related]
8. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines.
Russell SJ; Barber GN
Cancer Cell; 2018 Apr; 33(4):599-605. PubMed ID: 29634947
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site.
Lopes A; Feola S; Ligot S; Fusciello M; Vandermeulen G; Préat V; Cerullo V
J Immunother Cancer; 2019 Jul; 7(1):174. PubMed ID: 31291991
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens.
Luo Y; Lin C; Zou Y; Ju F; Ren W; Lin Y; Wang Y; Huang X; Liu H; Yu Z; Liu P; Tan G; Yuan Q; Zhang J; Huang C; Xia N
Oncoimmunology; 2020; 9(1):1726168. PubMed ID: 32117591
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.
Marelli G; Howells A; Lemoine NR; Wang Y
Front Immunol; 2018; 9():866. PubMed ID: 29755464
[TBL] [Abstract][Full Text] [Related]
13. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeted delivery of copper-manganese biomineralized oncolytic adenovirus for colorectal cancer immunotherapy.
Li YS; Ye LY; Luo YX; Zheng WJ; Si JX; Yang X; Zhang YN; Wang SB; Zou H; Jin KT; Ge T; Cai Y; Mou XZ
Acta Biomater; 2024 Apr; 179():243-255. PubMed ID: 38458511
[TBL] [Abstract][Full Text] [Related]
15. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages.
Shen Z; Liu X; Fan G; Na J; Liu Q; Lin F; Zhang Z; Zhong L
J Transl Med; 2023 Nov; 21(1):842. PubMed ID: 37993941
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.
Capasso C; Hirvinen M; Garofalo M; Romaniuk D; Kuryk L; Sarvela T; Vitale A; Antopolsky M; Magarkar A; Viitala T; Suutari T; Bunker A; Yliperttula M; Urtti A; Cerullo V
Oncoimmunology; 2016 Apr; 5(4):e1105429. PubMed ID: 27141389
[TBL] [Abstract][Full Text] [Related]
17. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO; Hong J; Yoon AR
Front Immunol; 2022; 13():953410. PubMed ID: 36091031
[TBL] [Abstract][Full Text] [Related]
18. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.
Nistal-Villan E; Bunuales M; Poutou J; Gonzalez-Aparicio M; Bravo-Perez C; Quetglas JI; Carte B; Gonzalez-Aseguinolaza G; Prieto J; Larrea E; Hernandez-Alcoceba R
Mol Cancer; 2015 Dec; 14():210. PubMed ID: 26671477
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Oncolytic Virus-Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models.
Veinalde R
Methods Mol Biol; 2020; 2058():213-227. PubMed ID: 31486040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
